Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase IIb, randomizado, duplo-cego e controlado por placebo de Elismetrep (K-304) no tratamento da enxaqueca

25 de setembro de 2026 atualizado por: TriGemX Bio, Inc.

Um estudo de fase IIB, randomizado, duplo-cego e controlado por placebo de Elismetrep (K-304) no tratamento da enxaqueca: uma série de doses será avaliada

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

431

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35205
        • Central Research Associates, LLC (CRA) dba Flourish Research
      • Mobile, Alabama, Estados Unidos, 36608
        • AMR Mobile
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85710
        • Wake Research/ Tucson Neuroscience Research
    • California
      • Canoga Park, California, Estados Unidos, 91303
        • Hope Clinical Research
      • Encino, California, Estados Unidos, 91316
        • WR-PRI, LLC (Encino)
      • Huntington Beach, California, Estados Unidos, 92647
        • Marvel Clinical Research
      • La Mesa, California, Estados Unidos, 91942
        • Eximia Research - CA
      • Lemon Grove, California, Estados Unidos, 91945
        • Synergy San Diego
      • Newport Beach, California, Estados Unidos, 92660
        • WR-PRI, LLC (Newport Beach)
      • Oceanside, California, Estados Unidos, 92056
        • Excell Research, Inc.
      • Pomona, California, Estados Unidos, 91767
        • Empire Clinical Research
      • Riverside, California, Estados Unidos, 92503
        • Artemis Institute for Clinical Research - Riverside
      • San Diego, California, Estados Unidos, 89109
        • Acclaim Clinical Research
      • San Diego, California, Estados Unidos, 92103
        • Artemis Institute for Clinical Research - San Diego
      • Walnut Creek, California, Estados Unidos, 94598
        • Diablo Clinical Research, Inc.
      • West Hills, California, Estados Unidos, 91307
        • Focus Clinical Research
    • Connecticut
      • Cromwell, Connecticut, Estados Unidos, 06416
        • CT Clinical Research
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30329
        • DelRicht Research
      • Stockbridge, Georgia, Estados Unidos, 30281
        • Clinical Research Atlanta - Stockbridge
    • Idaho
      • Boise, Idaho, Estados Unidos, 83704
        • Northwest Clinical Trials
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Cedar Crosse Research Center
      • Flossmoor, Illinois, Estados Unidos, 60422
        • Healthcare Research Network II, LLC
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66202
        • Collective Medical Research
      • Wichita, Kansas, Estados Unidos, 67207
        • Alliance for Multispecialty Research
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40213
        • L-MARC Research Center
    • Louisiana
      • Chalmette, Louisiana, Estados Unidos, 70043
        • Crescent City Headache & Neurology Center
      • New Orleans, Louisiana, Estados Unidos, 70115
        • DelRicht Research
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48104
        • Michigan Head Pain and Neurological Institute
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55402
        • Clinical Research Institute
    • Mississippi
      • Gulfport, Mississippi, Estados Unidos, 39503
        • DelRicht Research
    • Missouri
      • Hazelwood, Missouri, Estados Unidos, 63042
        • Healthcare Research Network
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, Estados Unidos, 89119
        • Las Vegas Clinical Trials
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87102
        • Albuquerque Clinical Trials, Inc.
    • New York
      • Amherst, New York, Estados Unidos, 14226
        • Dent Neurosciences Research Center
      • Manlius, New York, Estados Unidos, 13104
        • CNY Clinical Research
      • Rochester, New York, Estados Unidos, 14609
        • Rochester Clinical Research
      • Williamsville, New York, Estados Unidos, 14221
        • Upstate Clinical Research Associates LLC
    • North Carolina
      • Greensboro, North Carolina, Estados Unidos, 27405
        • Headache Wellness Center
      • High Point, North Carolina, Estados Unidos, 27260
        • Peters Medical Research
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45212
        • CTI Clinical Research Center
    • Oklahoma
      • Edmond, Oklahoma, Estados Unidos, 73034
        • OK Clinical Research, LLC
      • Oklahoma City, Oklahoma, Estados Unidos, 73102
        • Hightower Clinical
      • Tulsa, Oklahoma, Estados Unidos, 74133
        • DelRicht Research
      • Yukon, Oklahoma, Estados Unidos, 73099
        • Tekton Research
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Summit Research Network
    • Pennsylvania
      • Allentown, Pennsylvania, Estados Unidos, 18103
        • Lehigh Center for Clinical Research
      • Philadelphia, Pennsylvania, Estados Unidos, 19114
        • Clinical Research Philadelphia, LLC
      • Scottdale, Pennsylvania, Estados Unidos, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Estados Unidos, 15478
        • Frontier Clinical Research, LLC
      • West Chester, Pennsylvania, Estados Unidos, 19380
        • Atlas-Clinical
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29406
        • Clinical Trials of South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37421
        • WR-ClinSearch
      • Knoxville, Tennessee, Estados Unidos, 37909
        • AMR Knoxville (Formerly NOCCR)
      • Nashville, Tennessee, Estados Unidos, 37203
        • Clinical Research Associates, Inc.
    • Texas
      • Austin, Texas, Estados Unidos, 78745
        • Tekton Research
      • Austin, Texas, Estados Unidos, 78737
        • Donald J Garcia Jr, MD, PA
      • Dallas, Texas, Estados Unidos, 75251
        • FutureSearch Trials of Dallas, LP
      • Houston, Texas, Estados Unidos, 77024
        • Victorium Clinical Research LTD CO
      • Splendora, Texas, Estados Unidos, 77372
        • APD Clinical Research
      • Waxahachie, Texas, Estados Unidos, 75165
        • ClinPoint Trials
    • Utah
      • Ogden, Utah, Estados Unidos, 84405
        • Advanced Research Institute
    • Virginia
      • Newport News, Virginia, Estados Unidos, 23606
        • Health Research of Hampton Roads, Inc.
    • West Virginia
      • Morgantown, West Virginia, Estados Unidos, 26505
        • Frontier Clinical Research, LLC
    • Wisconsin
      • Kenosha, Wisconsin, Estados Unidos, 53144
        • Clinical Investigation Specialist

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.

  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.

  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).

  4. Meet the following requirements:

    1. Is a male OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

    3. Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.

    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of reproductive potential and:

    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)

      • intrauterine hormone-releasing system (IUS)

      • bilateral tubal occlusion

      • vasectomised partner

      • sexual abstinence

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

      • male or female condom with or without spermicide

      • cap, diaphragm or sponge with spermicide

      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.

  6. Participant is able to read, understand and complete the study questionnaires and diary.

  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.

  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.

  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.

  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).

  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.

  6. Participant was >50 years old at age of first migraine onset.

  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].

  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.

  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.

  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

  13. Has a history of human immunodeficiency virus disease.

  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and electrocardiogram (ECG) related

  15. Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.

  16. Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.

  17. Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.

  18. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.

  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.

  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.

  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.

  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.

  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.

  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.

  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected hypersensitivity to trial product(s) or related products.

  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.

  29. Has any surgery scheduled for the duration of the trial.

  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).

  31. Has previous participation in this trial. Participation is defined as signed informed consent.

  32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.

  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Elismetrep (K-304) Dose Level 1

Participants received a single dose of elismetrep 2 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 2

Participants received a single dose of elismetrep 5 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 3

Participants received a single dose of elismetrep 10 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 4

Participants received a single dose of elismetrep 20 mg

Administered orally

Comparador de Placebo: Placebo

Participants received a single dose of elismetrep-matched placebo

Administered orally

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pain Freedom
Prazo: 2 hours post-dose

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

2 hours post-dose

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Prazo: up to 7 days after administration of study therapy
up to 7 days after administration of study therapy
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Prazo: 2 hours post-dose

Assessed using the number of evaluable participants that reported the absence of their MBS

2 hours post-dose
Pain Relief
Prazo: 2 hours post-dose

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

2 hours post-dose
Freedom From Photophobia
Prazo: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

2 hours post-dose
Freedom From Phonophobia
Prazo: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

2 hours post-dose
Freedom From Nausea
Prazo: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

2 hours post-dose
The Probability of Requiring Rescue Medication
Prazo: 24 hours post-dose

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

24 hours post-dose
Sustained Pain Freedom
Prazo: From 2 to 24 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest

From 2 to 24 hours
Sustained Pain Relief
Prazo: From 2 to 24 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 24 hours
Sustained Pain Freedom
Prazo: From 2 to 48 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

From 2 to 48 hours
Sustained Pain Relief
Prazo: From 2 to 48 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Prazo: Up to 7 days after administration of study therapy

Serious adverse events were assessed in the Safety Analysis Set.

Up to 7 days after administration of study therapy

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de março de 2025

Conclusão Primária (Real)

4 de agosto de 2025

Conclusão do estudo (Real)

4 de agosto de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

21 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de fevereiro de 2025

Primeira postagem (Real)

26 de fevereiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever